
PaySign Inc (PAYS) Stock Forecast & Price Target
PaySign Inc (PAYS) Analyst Ratings
Bulls say
PaySign is a promising company with strong revenue and adjusted EBITDA growth, a positive outlook for their Patient Affordability programs, and plans for international expansion and diversification. Despite a decrease in serviced centers, their Plasma Donor Compensation segment has seen an increase in revenue, solidifying their position in the pharmaceutical market. With a BUY rating and a price target of $12, analysts are optimistic about the company's future performance.
Bears say
PaySign is a company that has faced significant competition in their market and has relied heavily on a niche market of plasma donor compensation for a large portion of their revenue, making them vulnerable to changes in that industry. They also face regulatory compliance challenges and a moderate insider ownership that could make it difficult for minority shareholders to effect change. Despite recent success in their patient affordability programs, their international expansion efforts have yet to bear significant results.
This aggregate rating is based on analysts' research of PaySign Inc and is not a guaranteed prediction by Public.com or investment advice.
PaySign Inc (PAYS) Analyst Forecast & Price Prediction
Start investing in PaySign Inc (PAYS)
Order type
Buy in
Order amount
Est. shares
0 shares